Literature DB >> 1697098

Major autoantigenic sites of the (U1) small nuclear ribonucleoprotein-specific 68-kDa protein.

H J Netter1, H H Guldner, C Szostecki, H Will.   

Abstract

A 68-kDa protein associated with (U1)snRNP is a major target for human autoantibodies to small ribonucleoprotein particles (snRNP) prevalent in a variety of inflammatory rheumatic diseases. The epitopes recognized by these antibodies were mapped by expression of subfragments of p68 cDNA in Escherichia coli and testing of the corresponding recombinant proteins for immunoreactivity with sera of patients with autoimmune diseases. Three of four antigenic regions were analysed in detail. The immunodominant autoantigenic region was found to coincide with the RNA-binding domain of the p68 protein and was shown to contain a nested set of overlapping discontinuous epitopes. Two additional non-overlapping major antigenic domains were localized in the carboxy-terminal half of the p68 protein. Each of these two carboxy-terminal domains was shown to contain more than one conformation-dependent epitope. Taking into account previous mapping studies, the data demonstrate that p68 contains at least four antigenic regions, each of which harbours multiple epitopes which are recognized in a patient-specific manner.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697098     DOI: 10.1111/j.1365-3083.1990.tb02906.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  10 in total

1.  Key residues revealed in a major conformational epitope of the U1-70K protein.

Authors:  E Welin Henriksson; M Wahren-Herlenius; I Lundberg; E Mellquist; I Pettersson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

Review 2.  Methods of epitope mapping.

Authors:  I Pettersson
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

Review 3.  Mapping of epitopes recognized by anti-(U1)RNP autoantibodies.

Authors:  H H Guldner
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

Review 4.  The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases.

Authors:  Nicole H Kattah; Michael G Kattah; Paul J Utz
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

5.  Mapping epitopes of U1-70K autoantibodies at single-amino acid resolution.

Authors:  David James Haddon; Justin Ansel Jarrell; Vivian K Diep; Hannah E Wand; Jordan V Price; Stephanie Tangsombatvisit; Grace M Credo; Sally Mackey; Cornelia L Dekker; Emily C Baechler; Chih Long Liu; Madoo Varma; Paul J Utz
Journal:  Autoimmunity       Date:  2015-08-31       Impact factor: 2.815

6.  Systemic lupus erythematosus murine monoclonal DNA-binding antibodies recognize cytoplasmic and nuclear phosphorylated antigens that display cell cycle redistribution in HEp-2 cells.

Authors:  E Bronze-da-Rocha; C Machado; N A Staines; C E Sunkel
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

7.  Characterization of an HLA-DR4-restricted T cell clone recognizing a protein moiety of small nuclear ribonucleoproteins (UsnRNP).

Authors:  G Wolff-Vorbeck; W Hackl; S Fenning; U Krawinkel; R Lührmann; H H Peter; M Schlesier
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

8.  Sequential autoantigenic determinants of the small nuclear ribonucleoprotein Sm D shared by human lupus autoantibodies and MRL lpr/lpr antibodies.

Authors:  J A James; M J Mamula; J B Harley
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

9.  Epitopes of the Onchocerca volvulus RAL1 antigen, a member of the calreticulin family of proteins, recognized by sera from patients with onchocerciasis.

Authors:  L A Rokeach; P A Zimmerman; T R Unnasch
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

10.  Cellular localization, expression, and structure of the nuclear dot protein 52.

Authors:  T Sternsdorf; K Jensen; D Züchner; H Will
Journal:  J Cell Biol       Date:  1997-07-28       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.